Stay updated with breaking news from Analyst Event. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host a hybrid Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern Time in New York. The event...
Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host a hybrid Investor & Analyst Event on Tuesday,...
Operator: Greetings and welcome to the Marinus Pharmaceuticals’ Second Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode.
Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62
Operator: Greetings and welcome to the Marinus Pharmaceuticals’ First Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode.